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Abstract
Introduction: In vitro human diagnostic (IVD) company recalls are a common practice aimed to either minimize a potential error or eliminate an 
existing failure. In this case report, we aim to provide a critical analysis of a recent IVD recall and to provide a practical framework about what to do 
when an IVD company recalls product(s) based on the International Organization for Standardization - ISO 15189:2012 standard.
Case report: In 2014, Abbott Laboratories® (Green Oaks, IL) published an urgent field safety notice regarding a product recall (Architect Intact pa-
rathyroid hormone (PTH) Assay List Number 8K25) with immediate action required. The IVD company explained the reasons for the recall as follows: 
i) Abbott has confirmed that a performance shift in the Architect Intact PTH assay has the potential to generate falsely elevated results on patient 
samples; ii) results generated with impacted lots may demonstrate a positive shift relative to those generated with previous reagent and/or cali-
brator lots. This issue may also impact established Architect Intact PTH reference ranges; iii) the magnitude of shift averages approximately 13% to 
45%; iv) Abbott Architect Intact PTH controls do not detect the shift; and v) all current reagent, calibrator, and control inventory are impacted. The 
recall could have resulted in ~40,000 inaccurate laboratory tests reported by 18 laboratories from Italy (Lombardy region). 
Conclusion: IVD company recalls have a serious impact on the patient safety and require a thorough investigation and responsible approach to 
minimize the possible damage. Medical laboratories accredited according to the ISO 15189 standard have procedures in place to manage such situa-
tions and ensure that patient safety is maintained when such recalls are issued.
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Analytical processes in laboratories are error sus-
ceptible. However, failures in adhering to best 
practices of either analytical procedures or quality 
management can jeopardize patient safety (1,2). 
Experts have encouraged and developed produc-
tive discussions about this topic and the relevant 
assumptions of error responsibility (3,4). With an 
objective to guarantee patient safety, medical lab-
oratory directors are continuously improving their 
quality management system through certification 
and accreditation. Medical laboratory certification 
(i.e., by the International Organization for Stand-
ardization-ISO 9001:2008 standard) aims to assess 
conformity to a specific documented system with-
out verifying the technical competence, whereas 
accreditation (i.e., by ISO 15189:2012 standard) is a 
process aimed at providing an independent ap-
praisal and recognition—by one expert medical 
laboratory professional—of the specific compe-
tence of testing (5,6). The processes of validation, 
verification, and non-conformity management are 
essential for quality system maintenance in ac-
credited laboratories (6). Unfortunately, only few 
medical laboratories worldwide are accredited (7), 
and some clinical directors prefer certification to 
the accreditation process when the laboratories 
are located inside a hospital. 
To verify if each laboratory test is both precise and 
accurate, quality control (i.e., both internal and ex-
ternal) procedures are performed. Presently, every 
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in vitro human diagnostic (IVD) company provides 
proprietary internal quality control materials for 
each product kit. However, sometimes a recall can 
happen because of issues occurring in the produc-
tion/control phases. Briefly, according to the Euro-
pean Commission, recall means any measure 
aimed at achieving the return of a device that has 
already been made available to the end user (8). 
Nevertheless, laboratory professionals are aware 
that IVD company recalls are an usual practice 
aimed to either minimize a potential error or elimi-
nate an existent failure (9). In this case report we 
aimed to critically analyze a recent IVD recall and 
to provide a practical framework about what to do 
when an IVD company recalls product(s), based on 
the ISO 15189:2012 standard (6).
Case report
On February 12th 2014, the Abbott Laboratories® 
(Green Oaks, IL) published one urgent field safety 
notice (recall) regarding an IVD product kit: Archi-
tect Intact parathyroid hormone (PTH) Assay List 
Number 8K25, requiring immediate action (10). 
The IVD company (10) explained the recall as fol-
lows: 
•	 A performance shift in the assay may generate 
falsely elevated results on samples;
•	 Consequent results may demonstrate a positive 
shift in respect to previous reagent/calibrator 
lots, with a possible impact on established ref-
erence intervals;
•	 The shift magnitude is averaging approximate-
ly 13% to 45%;
•	 Kit-included controls do not detect the shift;
•	 All kit inventory (i.e., reagent, calibrator, and 
control) is impacted.
As common practice, the Italian Health Ministry 
started to disseminate news about this important 
recall on the website a few days later (February 
21th, 2014) (11). Obviously, the recall had an impact 
only on the laboratories that were using this kit.
Nonetheless, Italian mass media (12,13) widely 
propagated the news of the Abbott Laboratories® 
recall and the consequent impact on the medical 
laboratory of the hospital involved. Briefly, the fol-
lowing was reported: i) ~3,500 patients went to 
the hospital laboratory for PTH testing between 
February 2013 to February 2014 and had their tests 
recalled due to unreliable PTH results; ii) staff from 
N.A.S. (Nucleo Antisofisticazioni e Sanità, the Ital-
ian health enforcing agency (14) comparable to 
the United States Food and Drug Administration 
(FDA)) requested all relevant documents in order 
to justify the substantial patient recall i.e., the re-
call report from Abbott, the official business agree-
ment between the IVD company and medical lab-
oratories, the corrective action plan, a list of pa-
tients with recalled test results, and a list of physi-
cians contacted by the laboratory professionals; iii) 
there was a quest by all laboratories that used the 
same kit (N = 18) for accurate PTH test results 
(15,16).
Discussion
Medical errors that jeopardize patient safety have 
attracted a great deal of public attention, especial-
ly when the situation demands the review of a 
large numbers of patient records or a recall of pa-
tient test results, as in this Italian case. Recently, 
the United States Department of Justice released 
that another IVD company was penalized to pay to 
United States $262 million plus interest to resolve 
malpractices related to the Advantage Intact PTH 
assay and four other manufactured assays (17).
To the best of our knowledge, the laboratories in-
volved in the Italian recall were not accredited un-
der the ISO 15189 standard; moreover, they were 
unable to recognize the above problem before the 
Abbott recall. It is likely that the laboratory manag-
ers failed to satisfy the formal method verification 
and did not provide to their quality managers the 
essential information for performing the needed 
preventive/corrective actions regarding this non-
conformity. 
According to the ISO 15189 standard, laboratory 
quality managers should: i) select both analyzers 
and reagents, which have been validated by the 
producer for their intended use and show prefer-
ence to procedures specified in the IVD instruc-
tions for use (i.e., the datasheet from the intact 
PTH assay for Architect, Abbott Laboratories®); ii) 
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verify the performance characteristics declared by 
the producer to confirm the datasheet informa-
tion before it is introduced into routine use; and iii) 
plan quality control procedures to verify the quali-
ty of the results, e.g., by internal- and external-
quality controls (6). Probably Abbott laboratory-
customers’ had performed their internal quality 
control using exclusively proprietary (Abbott) PTH 
controls. Otherwise, PTH result variability could 
have been prevented by third-party control mate-
rials-independent from calibrator materials-either 
instead of or in addition to any control materials 
supplied by the analyzer manufacturer (Abbott). 
Moreover, the reported variability was undetecta-
ble when using Abbott Architect Intact PTH con-
trols (10). However, if this implies that IVD compa-
nies provide quality control materials that are una-
ble to detect non-conformity in their IVD diagnos-
tic medical devices, then the same IVD companies 
should abstain from providing quality control ma-
terials (8,18,19).
The PTH external quality assessment (EQA) annual 
report of 2013 (when laboratories used the kit re-
called by Abbott in February 2014) showed pro-
ducers’ inter-method “inaccuracy” for PTH quality 
samples (i.e., with low-, medium- and high-con-
centrations of PTH). The inaccuracy of Abbott-Ar-
chitect for PTH assay were higher than either Sie-
mens-Advia Centaur, Siemens-Immulite, DiaSorin-
Liaison, or Tosoh-AIA for samples with both low- 
and medium-concentration of PTH (20). Laborato-
ry quality managers that used Architect to meas-
ure PTH could have assessed the data from the 
EQA report plus the internal quality control data to 
investigate the processed sample commutability 
following CLSI EP14-A3 document (21). With the 
CLSI EP14-A3 protocol, laboratory quality manag-
ers are able to distinguish between the effects 
caused by measurement procedure malfunctions 
and those caused by the use of artificial or human-
based sample processing (e.g., quality control 
samples). Moreover, from an analytical point-of-
view, the bias due to the Intact PTH assay of Ab-
bott Laboratories on Architect is not a new out-
come. Monge et al. compared intact PTH from Ar-
chitect (Abbott Laboratories®, Green Oaks, IL, USA) 
with that from Elecsys (Roche Diagnostics, Meylan, 
France) and the PTH results from the Architect kit 
were significantly higher (approximately +30%) 
than those obtained using the kit from Elecsys 
(22). However, no adjustments were reported by 
Abbott leaving us to speculate as to whether or 
not the 18 laboratories involved, belonging to the 
same Italian region (i.e., Lombardia) and using the 
same kit on about 40,000 patient samples, under-
taken any corrective action. Was the 13% to 45% 
shift recently claimed by Abbott in addition to the 
already known +30% (demonstrated by Monge et 
al. (22))? Should it be regarded as a further correc-
tion? In the latter hypothesis, such skewed PTH 
analyses could undoubtedly jeopardize patient 
safety. 
Clinically, the measure of PTH is a second-level ex-
amination, requested by physicians with other 
tests: e.g., calcium to elucidate a hyperparathy-
roidism hypothesis. Consequently, most patients 
with hyperparathyroidism show both elevated 
PTH and calcium levels (23). Normocalcemic pri-
mary hyperparathyroidism, characterized by an in-
creased PTH concentration in the absence of hy-
percalcemia, has been identified (24). In the pre-
sent case, dutiful physicians may have abstained 
from the appropriate patient treatments’ as a con-
sequence of the large average shift reported by 
Abbott (up to 45%) (10). It is well-known that PTH 
shows a rather wide biological variation, both 
within- and between-subjects (25.3% CVI and 
43.4% CVG, respectively), and a low index of indi-
viduality that advices against the use of the refer-
ence interval and rather suggests the longitudinal 
evaluation of the same individual (25). Therefore, 
each patient should have increasing PTH levels 
with time, and relevant feedback to the laboratory 
should have arrived. However, this was not the 
case, suggesting that individual PTH data was only 
compared with the reference interval and not 
against the patient’s previous results, which is the 
preferred way for evaluating patient’s data over 
time, especially for analytes such as PTH (26).
When an IVD company shares their recall, the lab-
oratory quality managers should: i) look for all re-
sults reported using either the reagent or instru-
ment affected; ii) classify the results reported 
based on the potential risk involved in misleading 
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physicians (i.e., borderline results that require pos-
sible exchanges regarding “clinical decision lim-
its”); iii) find alternative methods to re-test the pa-
tient samples that showed borderline results (the 
method should be selected based on both similar 
performance indicated in the EQA report and 
commutability) and if the patient sample is missing, 
the patient should be contacted for new sample 
collection; and iv) formally inform the physicians (or 
whoever ordered the laboratory test) that the re-
sults from the 2nd determination might modify the 
clinical decision; otherwise, the formal communica-
tion to the physician is facultative (if the 2nd result 
remains like the 1st), but all results should be trace-
able and maintained in the laboratory (Figure 1).
This case report is by itself an indicator that har-
monization among IVD producers is both urgent 
and necessary. The above laboratories (i.e., 18 lab-
oratories from Northern Italy) needed to replace 
the Abbott method after the recall. So, quality 
managers should revise the associated reference 
intervals and clinical decision values taking into 
account all causes of inaccuracy (6). Harmonization 
among IVD producers would enable laboratories 
to replace their methods from one manufacturer 
to another, without method verification. Unfortu-
nately, this is not currently possible. Consequently, 
the agreement between different IVD companies 
(i.e., Abbott with another IVD company) to guaran-
tee either instrument or reagent replacement 
when a product’s failure occurs is not enough. 
Case-by-case evaluation should be performed by 
laboratory quality managers in order to make the 
best choice when replacement is needed.
In conclusion, the major criticism of the recent Ab-
bott® recall (10) is about its impact on the patient 
safety. Medical laboratories accredited according 
to the ISO 15189 standard (6) are able to guarantee 
patient safety when IVD companies start a recall 
procedure. Presently, the main concern among all 
laboratory professionals, being informed about a 
company’s recall, is the quality. All the documents 
requested by the NAS (14) (see above) from the 
laboratory of the Italian hospital are easily tracea-
ble, and such is the case with every laboratory ac-
credited by the ISO 15189:2012 standard (6). In our 
opinion, the medical laboratory accreditation pro-
cess is the best way to guarantee patient safety in 
laboratory diagnostics. We also believe that the 
procedure for industry recall, viewed as a common 
Figure 1. Flow chart outlining the ideal IVD company recall re-
sponse protocol.
*We suggest classifying a potential and clinically significant 
change in the 2nd determination using the reference change 
value (RCV) equation as follows: RCV = 21/2 × Z × (CVI2 + CVA2)1/2; 
where Z is a constant depending on the probability, 1.96 is most 
often considered significant, that is, P < 0.05, CVI is the within-
subject biological variation obtained from the Westgard data-
base (27), and CVA is the analytical coefficient of variation from 
our internal quality control. Critical Difference (CD) needs to 
be determined according to the formula: CD = [(determination 
before IVD company recall – determination after IVD company 
recall “second method”) / determination before IVD company 
recall] × 100%. Finally, the CD should be compared to the RCV. 
Only a CD higher than the RCV should be considered clinically 
significant. Desirable specification for imprecision (DSI) derived 
from biologic variation (27) could be used as an acceptance cri-
teria for re-testing patient samples after an IVD company recall.
Find laboratory reports involving
either IVD reagents, instruments,
or devices being recalled.




























ordered the laboratory test.
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practice to minimize a potential error, should be 
revised, and harmonization among IVD manufac-
turers should be considered with highest priority.
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